Vega, R. B., O’Mahony, G., Barbour, A. M., Yu, H., Knöchel, J., Brengdahl, J., Hochdörfer, T., Bergenholm, L., Carlsson, E. T., Ahnmark, A., Underwood, C. R., Rudvik, A., Carter, D., Laru, J., Gutgsell, A., Twaddle, L., Garkaviy, P., Bogstedt, A., Hurt-Camejo, E., Miliotis, T., Ryaboshapkina, M., Hober, A., Hubbard, B., Serrano-Wu, M., Kaushik, V., Geschwindner, S., McCarthy, M. C., Lindén, D., Rosenmeier, J. B. (2026). Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. Circulation. https://doi.org/10.1161/circulationaha.125.075973